DOCS — Doximity Inc
NYSE · Health Care · Health Care
- Latest Close
- $23.17
- 30-Day Move
- -47.1%
- Market Cap
- $3.0B
- Shares Outstanding
- 184,710,000
- P/E Ratio
- 12.73
- P/B Ratio
- 10.06
Doximity Inc
A read-only Alphactor snapshot forDoximity Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$23.17
30-Day Move
-47.1%
Market Cap
$3.0B
Shares Outstanding
184,710,000
P/E Ratio
12.73
P/B Ratio
10.06
$23.17
-47.1%last 90 delayed daily bars
90D High
$46.75
90D Low
$20.55
Avg Volume
3,317,423
Gross margin is running at 89.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 37.5%, useful for comparing DOCS against peers in Health Care.
DOCS is down 47.1% over the last 30 trading days shown on this page.
Latest operating income is $72M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$23.08
Rule of 40
66.7%
Latest Close
$23.17
30-Day Move
-47.1%
Market Cap
$3.0B
Shares Outstanding
184,710,000
P/E Ratio
12.73
P/B Ratio
10.06
ROE
20.6%
ROA
17.6%
Gross Margin
89.8%
Operating Margin
37.4%
Net Margin
37.5%
Debt / Equity
0
Current Ratio
6.97
Latest Revenue
$185M
Revenue
$185M
Gross Profit
$166M
Operating Income
$72M
Net Income
$62M
Gross Margin
8975.0%
Net Margin
3754.0%
Current Ratio
6.97
Debt / Equity
0.00
Fair Value
$23.08
Upside / Downside
-0.4%
Signal
Fairly Valued
Implied Growth
-2.2%
DCF
$42.21
EPV
$10.51
EV/Rev
$16.51
Growth Assumption
18.4%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$267M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative growth / decline priced in
Altman Z
12.21
Safe
Piotroski
9
Strong (7-9)
Cash Conversion
1.22x
Rule of 40
66.7%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $344M | $114M | $155M | $121M |
| 2023-12-31 | $419M | $125M | $113M | $173M |
| 2024-12-31 | $475M | $172M | $148M | $178M |
| 2025-12-31 | $570M | $230M | $223M | $267M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Two Sigma Advisers
Filed 2025-11-14
--
--
Vanguard Group
Filed 2025-11-07
$934M
+0.1%
BlackRock
Filed 2024-08-13
$301M
--
Geode Capital Management
Filed 2025-11-12
$281M
+5.3%
Renaissance Technologies
Filed 2025-05-14
$178M
--
Invesco
Filed 2025-11-13
$170M
+22.9%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.